^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
SPOT-LIGHT HER2 CISH Kit

Type:
FDA Approved
Related tests:

Details

Evidence
News
The SPOT-Light® HER2 CISH Kit is intended to quantitatively determine HER2 gene amplification in formalin- fixed, paraffin-embedded (FFPE) breast carcinoma tissue sections using chromogenic in situ hybridization (CISH) and hrightfield microscopy. This test should be performed in a histopathology laboratory. The SPOT-Light® HER2 CISH Kit is indicated as an aid in the assessment of patients for whom Hercepting (trastuzumnab) treatment is being considered. The assay results are intended for use as an adjunct to the clinicopathological information currently being used as part of the management of breast cancer patients. Interpretation of test results must be made within the context of the patient's clinical history by a qualified pathologist.
Cancer:
Breast Cancer
Gene:
HER-2 (Human epidermal growth factor receptor 2)
Drug:
Herceptin (trastuzumab)
Method:
Chromogenic In Situ Hybridization (CISH)
Approvals
Date
Cancer
Gene
Drug
By